Table 2.
Summary of study results
| Study | Number | Doses used (ranges) | Mean (mg/2 weeks) | Antipsychotic use (%) | Treatment failure over study period—n (%) | Treatment success at 6 months (%) | EPSE (%) | Anticholinergic Rx (%) |
|---|---|---|---|---|---|---|---|---|
| Agrup-Andersson et al. (1974) | 29 | Mean 40.7 mg/2 weeks (10–60 mg) | 40.7 | 68 | 2 (7) | 93 | 41 | |
| Agrup-Andersson et al. (1974) | 27 | Mean 40 mg/4 weeks (10–30 mg) | 20 | 6 (22.2) | 77.8 | 36 | ||
| Chiliza et al. (2016) | 207 | Mean 11. 6 mg/2 weeks (10–30 mg) | 11.6 | 0 | 33 (19.4) | 90.3a | 33 | 33 |
| Cookson (1987) | 7 | Mean 333 mg/2 weeks (100–800 mg) | 333 | not stated | 1 (14.3) | 91.5a | ||
| Cookson (1987) | 9 | Mean 118 mg/2 weeks (50-400 mg) | 118 | not stated | 3 (33.3) | 80.3a | ||
| Dencker et al. (1980) | 30 | Mean 140 mg/4 weeksb (not stated) | 70 | 0 | 4 (13.3) | 86.7 | ||
| Gottfries and Green (1974) | 58 | Mode 40 mg/2 weeks (20–60 mg) | 40 | not stated | 36 (62) | 92.7 | ||
| Johnson et al. (1987) | 31 | Mean 9 mg/week (4–20 mg) | 18 | 0 | 2 (6.5) | 93.5 | ||
| Johnson et al. (1987) | 28 | Mean 6 mg/week (1.7–10 mg) | 12 | 0 | 5 (17.8) | 82.2 | ||
| Kelly et al. (1977) | 15 | 40 mg every 3 weeks | 26.66 | 0 | 1 (6.7) | 95.3a | ||
| Kelly et al. (1977) | 15 | 20 mg every 3 weeks | 13.33 | 0 | 3 (20) | 86.7a | ||
| Knights et al. (1979) | 28 | 40 mg every 3 weeks | 26.66 | 0 | 10 (35.7) | 64.3 | 71 | 43 |
| Laux et al. (2010) | 94 | 36.4 | 45 | 18 (19.1) | 80.9 | |||
| McCreadie et al. (1988) | 12 | Mean 50 mg/3 weeks (50–100 mg) | 33.33 | not stated | 3 (25) | 87.5a | ||
| Pach et al. (1998), Finkbeiner et al. (1998) | 18 | Mean 22.4 mg/2 weeks (5–40 mg/1–4 weeks) | 22.4 | 38.9 | 3 (16.7) | 91.4 | 22 | 28 |
| Pach et al. (1998), Finkbeiner et al. (1998) | 25 | 20 mg every 2 weeks | 20 | 60 | 6 (24) | 88 | 12 | 44 |
| Pach et al. (1998), Finkbeiner et al. (1998) | 19 | 10 mg every 2 weeks | 10 | 42.1 | 6 (31.6) | 74 | 26 | 53 |
| Pinto et al. (1979) | 31 | Mean 36.6 mg/3 weeks (not stated) | 24.4 | 3.2 | 0 (0) | 100 | 42 | |
| Shajahan et al. (2010) | 43 | Median 60 mg/2 weeks (20–250 mg) | 60 | 40 | 33 (76.7) | 87.5 | ||
| Steinert et al. (1986) | 16 | Mode 40 mg/2 weeks (20–40 mg) | 40 | 0 | 7 (44) | 78a | ||
| Wistedt (1981), Wistedt et al. (1982) | 8 | Mean 27.5 mg/3 weeks (10–40 mg) | 18.34 | 0 | 3 (37.5) | 62.5 | ||
| Wistedt (1981), Wistedt et al. (1982) | 8 | 0 (Placebo) | 0 | 0 | 6 (75) | 25 | ||
| Wistedt and Ranta (1983) | 17 | Mean 31 mg/3 weeks (10–40 mg) | 20.66 | 50 | 7 (43.8) | 94.2 |
*a Calculated
bFlupentixol palmitate doses have been converted to flupentixol decanoate equivalents